Gene: ABL1 ×
Source: BEFREE ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913459
rs121913459
ABL1
0.020 GeneticVariation BEFREE The BCR-ABL T315I kinase domain mutation is insensitive to dasatinib therapy for Philadelphia-positive acute lymphoid leukemia (Ph + ALL) patients. 22587422

2012
dbSNP: rs121913459
rs121913459
ABL1
0.020 GeneticVariation BEFREE MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. 16990603

2007
dbSNP: rs1057519773
rs1057519773
ABL1
0.010 GeneticVariation BEFREE At the first relapse, an examination of the bone marrow revealed a transformation into acute lymphoblastic leukemia and an F317L mutation in BCR-ABL1 gene, which responded preferentially to nilotinib over dasatinib. 24532437

2014
dbSNP: rs121913451
rs121913451
ABL1
0.010 GeneticVariation BEFREE At the first relapse, an examination of the bone marrow revealed a transformation into acute lymphoblastic leukemia and an F317L mutation in BCR-ABL1 gene, which responded preferentially to nilotinib over dasatinib. 24532437

2014
dbSNP: rs121913448
rs121913448
ABL1
0.010 GeneticVariation BEFREE The Ph (+) ALL patient had a Glu255Lys mutation in exon 5 and a Thr315Ile mutation in exon 7. 18603297

2008
dbSNP: rs387906517
rs387906517
ABL1
0.010 GeneticVariation BEFREE The Ph (+) ALL patient had a Glu255Lys mutation in exon 5 and a Thr315Ile mutation in exon 7. 18603297

2008